(Q42541697)

English

Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma

scientific article published on May 1998

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 November 2017

Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma (English)

1 reference

Europe PubMed Central

2 November 2017

1 reference

based on heuristic

inferred from title

author name string

Drance SM

1

1 reference

Europe PubMed Central

2 November 2017

Crichton A

2

1 reference

Europe PubMed Central

2 November 2017

Mills RP

3

1 reference

Europe PubMed Central

2 November 2017

language of work or name

0 references

publication date

1 May 1998

1 reference

Europe PubMed Central

2 November 2017

American Journal of Ophthalmology

1 reference

Europe PubMed Central

2 November 2017

125

1 reference

Europe PubMed Central

2 November 2017

5

1 reference

Europe PubMed Central

2 November 2017

585-592

1 reference

Europe PubMed Central

2 November 2017

Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders

2 references

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900019-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900019-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ambulatory blood pressure monitoring in glaucoma. The nocturnal dip.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900019-1

7 January 2021

Adverse effects experienced by patients taking timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900019-1

7 January 2021

Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900019-1

7 January 2021

Topical ophthalmic beta-adrenergic blockade for the treatment of glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900019-1

7 January 2021

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900019-1

7 January 2021

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900019-1

7 January 2021

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900019-1

7 January 2021

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900019-1

7 January 2021

Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900019-1

7 January 2021

Hypertension, Perfusion Pressure, and Primary Open-angle Glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900019-1

7 January 2021

Ocular beta-blockers and systemic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900019-1

7 January 2021

A comparative study of the effects of timolol and latanoprost on blood flow velocity of the retrobulbar vessels.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900019-1

7 January 2021

Autoregulation of ocular blood flow during changes in intraocular pressure. Preliminary results.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900019-1

7 January 2021

Identifiers

10.1016/S0002-9394(98)00019-1

1 reference

Europe PubMed Central

2 November 2017

1 reference

Europe PubMed Central

2 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42541697&oldid=1961257002"